Release 5 Ballot

This page is part of the FHIR Specification (v5.0.0-ballot: R5 Ballot - see ballot notes). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B

Example MedicinalProductDefinition/equilidem-with-ing-and-auth (Narrative)

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: Not linked to any defined compartments

This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile MedicinalProductDefinition.

Generated Narrative

Id : equilidem-with-ing-and-auth

Identifier : Equilidem25

Combined Pharmaceutical Dose Form : tablet

Indication : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Legal Status Of Supply : Prescription only medicine

classification : B01A

Ingredients :

Role : active

substance : Equilidonium Phosphate

- Presentation
* 22 ml/1 tablet

Role : excipient

substance : Calcium Carbonate

- Presentation
* 3 ml/tablet

Names

- ProductName
* Equilidem 2.5 mg film-coated tablets

Cross References

- Product
* Link to generic equivalent

Manufacturing Business Operations

- Manufacturer
* EquiliDrugCo Processing Inc.

 

 

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.